Form 4 for EBS Emergent BioSolutions Inc.
Accepted 2023-06-13 00:00:00 ET · period of report 2023-06-09 · accession 0001367644-23-000119 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-06-13 | 2023-06-09 | EBS | Kramer Robert | Pres, CEO, Dir | A - Grant | $0.00 | +212.3K | 506.1K | +72% | $0 |
| D | 2023-06-13 | 2023-06-09 | EBS | Kramer Robert | Pres, CEO, Dir | A - Grant | $0.00 | +141.5K | 535.1K | +36% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-06-09 | A | A | 70,769 | $0.00 | 364,520 | D | — | — | (F1) Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company or the day prior to the annual shareholder meeting; whichever is earlier. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. |
| 2 | Common | Common Stock | 2023-06-09 | A | A | 141,539 | $0.00 | 506,059 | D | — | — | (F2) Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to both cumulative revenues and adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2023 and ending December 31, 2025, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%. |
| 3 | Derivative | Employee Stock Option (Right to buy) | 2023-06-09 | A | A | 141,539 | $0.00 | 535,051 | D | $8.39 · — to 2030-06-08 | 141,539 Common Stock | (F4) Represents the corrected number of securities owned due to a computational error in prior Form-4s (F3) Vests in three equal installments beginning on the day prior to the anniversary date of the grant. |